NEW: CIBMTR Research Allele and haplotype frequencies in high-resolution typing of HLA -A,-B, -C, -DRB1, and -DQB1 in 263,542 Thai voluntary stem cell donors Read more: 🔗pubmed.ncbi.nlm.nih.gov/42632272/
CIBMTR
@cibmtr.bsky.social
Research organization, collaborating with the global scientific community to increase survival and enrich quality of life for patients needing cellular therapy. Learn more at cibmtr.org.
NEW: CIBMTR Research Ibrutinib versus allogeneic HCT in relapsed/refractory del(17p) CLL/SLL Read more: 🔗pubmed.ncbi.nlm.nih.gov/42676008/
🔬 27 abstracts. 14 orals. 13 posters. 298 authors from 85 institutions. At #ASH26 (Dec. 12–14), CIBMTR will showcase research on expanding donor options, safer transplants, better AML MRD testing and real-world CAR T outcomes. See the schedule: cibmtr.org/CIBMTR/About... #CIBMTR #Research
NEW: CIBMTR Research Phase II study of posttransplant cyclophosphamide-based GVHD prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42674730/
Infections are common after CAR-T cells for multiple myeloma. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
NEW: CIBMTR Research Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42779338/
NEW: CIBMTR Research Group sequential clinical trial designs for composite endpoints incorporating recurrent and terminal events Read more: 🔗pubmed.ncbi.nlm.nih.gov/42496177/
Some medicines given after transplant have unique effects. Read about this BMT CTN study to learn more: cibmtr.org/Patient-Summ...
Just published: The November 2026 Newsletter from CIBMTR. Explore insights on kidney health in transplantation, working committee updates, new data resources, and recent research advances in HCT and cellular therapy. cibmtr.org/CIBMTR/About...
New: CIBMTR Research Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following axicabtagene ciloleucel or brexucabtagene CAR-T: CIBMTR research data Read more: 🔗pubmed.ncbi.nlm.nih.gov/42537846/
New: CIBMTR Research GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches Read more: 🔗pubmed.ncbi.nlm.nih.gov/42571736/
New: CIBMTR Research Challenges with expansion of cell and gene therapy: A call for system-level action Read more: 🔗pubmed.ncbi.nlm.nih.gov/42586370/
🚨 Secure your spot at #Tandem27! Join HCT, cellular therapy, and gene therapy professionals for cutting-edge science, expert education, and valuable networking. Orlando, FL | 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
New: CIBMTR Research Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: Results from the ACCESS trial Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42616616/
New: BMT CTN Research Donor-specific transplant outcomes from BMT CTN 1702: A multicenter prospective biologic assignment trial Read more: 🔗pubmed.ncbi.nlm.nih.gov/42263667/
Looking to learn, connect, and collaborate? #Tandem27 brings together the HCT and cellular therapy community for four days of education, networking, and discovery. 📍 Orlando, FL | 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
New: BMT CTN Research Patient-reported outcomes in clinical trials: Lessons from the BMT CTN Read more: 🔗pubmed.ncbi.nlm.nih.gov/42641160/
Last chance! Abstract submissions for 2027 Tandem Meetings close tonight at 11:59 p.m. CT. If you've been putting finishing touches on your research, now's the time to submit for your chance to present. 📍Orlando, FL | Feb. 17-20, 2027 🔗www.tandemmeetings.com/Abstracts/Ab...
NEW: BMT CTN Research Interpreting cord blood transplant outcomes in BMT CTN 1702 Read more: 🔗pubmed.ncbi.nlm.nih.gov/42641163/
🚨 Don't miss your chance to submit an abstract for #Tandem27 Abstract submissions close tomorrow, Oct. 9, at 11:59 p.m. CT. Submit your latest research before time runs out! ⏰ 📍 Orlando, FL | Feb. 17-20, 2027 🔗 www.tandemmeetings.com/Abstracts/Ab...
📢 #Tandem27 registration is open! Join ASTCT and CIBMTR for the latest research, emerging therapies, and advances in transplantation and cellular therapy. 📍 Orlando, FL | 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
⏳ The countdown is on! Abstract submissions for #Tandem27 close this Friday, Oct. 9, at 11:59 p.m. CT. Share your latest research and connect with leaders in HCT, cellular therapy, and gene therapy. 📍 Orlando, FL | Feb. 17-20, 2027 🔗 www.tandemmeetings.com/Abstracts/Ab...
NEW: CIBMTR Research Fertility preservation in 2026: Current landscape in Europe and the United States for children and adolescents undergoing HCT-recommendations on behalf of the Westhafen Intercontinental Group Read more: 🔗pubmed.ncbi.nlm.nih.gov/42120917/
Ready to connect with leaders across the field? #Tandem27 brings together experts in HCT, cellular therapy, and gene therapy for four days of education, collaboration, and networking. 📍 Orlando, FL 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
NEW: CIBMTR Research Haploidentical versus HLA-matched unrelated donors for HCT in acute leukemia Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42323086/
The future of HCT, cellular therapy, and gene therapy starts at #Tandem27. Join experts, researchers, and clinicians as they share the latest advances shaping patient care. 📍 Orlando, FL | 📅 Feb. 17-20, 2027 Register: www.tandemmeetings.com/Registration...
Abstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more: www.tandemmeetings.com/Abstracts/Ab... @astct.bsky.social
NEW: CIBMTR Research Access challenges in alloHCT: Identifying at-risk US states by exploring social vulnerability, physician density, and unmet need Read more: 🔗pubmed.ncbi.nlm.nih.gov/42372215/
NOW AVAILABLE: 2014-2024 Non-Malignant Summary Slides. These slides detail the clinical practices, trends, and survival outcomes following HCT and cellular therapy, including gene therapy for non-malignant diseases. Learn more: cibmtr.org/CIBMTR/Resou...